Science Explorer Back to mapMap

Most cited papers from Astellas Pharma (Japan)

What are the most cited papers from Astellas Pharma (Japan)?

The most cited paper from Astellas Pharma (Japan) is "Identification of a Primary Target of Thalidomide Teratogenicity" (Takumi Ito, Hideki Ando, Takayuki Suzuki et al., 2010), with 2,136 citations. Next come "Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial" (1,375) and "Linking the p53 tumour suppressor pathway to somatic cell reprogramming" (1,136).

Showing 50 of 58 papers. Every paper with more than 158 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Identification of a Primary Target of Thalidomide Teratogenicity Takumi Ito, Hideki Ando, Takayuki Suzuki et al. · Science 11 Mar 2010 2,136
2 Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial Piet Ost, Dries Reynders, Karel Decaestecker et al. · Journal of Clinical Oncology 14 Dec 2017 1,375
3 Linking the p53 tumour suppressor pathway to somatic cell reprogramming Teruhisa Kawamura, Jotaro Suzuki, Yunyuan V. Wang et al. · Nature Open access Aug 2009 1,136
4 The genetic architecture of the human cerebral cortex Katrina L. Grasby et al. · Science Open access362 authors 19 Mar 2020 910
5 A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing Deng Pan, Aya Kobayashi, Peng Jiang et al. · Science Open access 4 Jan 2018 880
6 NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016 David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network Open access Mar 2016 739
7 Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Ernst-Rüdiger Kuse et al. · The Lancet Open access 27 Apr 2007 694
8 Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA Daisuke Kaida, Hajime Motoyoshi, Etsu Tashiro et al. · Nature Chemical Biology 22 Jul 2007 668
9 Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis Peter G. Pappas, C. M. F. Rotstein, Robert F. Betts et al. · Clinical Infectious Diseases 4 Sep 2007 642
10 YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts Takahito Nakahara, Masahiro Takeuchi, Isao Kinoyama et al. · Cancer Research Sep 2007 509
11 Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration Manish Verma, Britney N. Lizama, Charleen T. Chu · Translational Neurodegeneration Open access 25 Jan 2022 446
12 TRPA1 regulates gastrointestinal motility through serotonin release from enterochromaffin cells Katsura Nozawa, Eri Kawabata-Shoda, Hitoshi Doihara et al. · Proceedings of the National Academy of Sciences Open access 11 Feb 2009 413
13 Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine Hajime Konno, Tetsurou Handa, David E. Alonzo et al. · European Journal of Pharmaceutics and Biopharmaceutics 7 Jun 2008 385
14 pH- and ion-sensitive polymers for drug delivery Takayuki Yoshida, Tsz Chung Lai, Glen S. Kwon et al. · Expert Opinion on Drug Delivery Open access 9 Aug 2013 368
15 Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases Florence I. Raynaud et al. · Cancer Research Open access 15 Jun 2007 355
16 Trends in US Hospital Admissions for Skin and Soft Tissue Infections John Edelsberg, Charu Taneja, Marcus Zervos et al. · Emerging infectious diseases Open access Sep 2009 330
17 Selective elimination of messenger RNA prevents an incidence of untimely meiosis Yuriko Harigaya, Hirotsugu Tanaka, Soichiro Yamanaka et al. · Nature Jul 2006 326
18 Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project) Roberto Bernabei et al. · BMJ Open access 11 May 2022 317
19 Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · European Journal of Pharmacology 23 May 2013 317
20 Effect of (R)-2-(2-Aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective β3-Adrenoceptor Agonist, on Bladder Function Toshiyuki Takasu, Masashi Ukai, Shuichi Sato et al. · Journal of Pharmacology and Experimental Therapeutics 9 Feb 2007 315
21 Repetitive Closed-Skull Traumatic Brain Injury in Mice Causes Persistent Multifocal Axonal Injury and Microglial Reactivity Yoshitsugu Shitaka, Hien T Tran, Rachel E. Bennett et al. · Journal of Neuropathology & Experimental Neurology Open access 10 Jun 2011 315
22 A selective PIKfyve inhibitor blocks PtdIns(3,5)P2 production and disrupts endomembrane transport and retroviral budding Harold B.J. Jefferies, Frank T. Cooke, Parmjit Jat et al. · EMBO Reports Open access 11 Jan 2008 312
23 Proliferative and Nonproliferative Lesions of the Rat and Mouse Urinary System Kendall S. Frazier, John Curtis Seely, Gordon C. Hard et al. · Toxicologic Pathology 25 May 2012 303
24 Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis David W. Denning, Kieren A. Marr, Wendi M. Lau et al. · Journal of Infection Open access 7 May 2006 294
25 Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2 Shun‐ichiro Matsumoto, Chihiro Yamazaki, Koh‐hei Masumoto et al. · Proceedings of the National Academy of Sciences 2 Mar 2006 291
26 Discovery of Novel Forkhead Box O1 Inhibitors for Treating Type 2 Diabetes: Improvement of Fasting Glycemia in Diabetic db/db Mice Takeyuki Nagashima, Nobuharu Shigematsu, Riyo Maruki et al. · Molecular Pharmacology 25 Aug 2010 278
27 A Comparison of the Physical Stability of Amorphous Felodipine and Nifedipine Systems Patrick Jules Marsac, Hajime Konno, Lynne S. Taylor · Pharmaceutical Research 23 Aug 2006 266
28 Structural basis for the specific inhibition of heterotrimeric G q protein by a small molecule Akiyuki Nishimura, Ken Kitano, Jun Takasaki et al. · Proceedings of the National Academy of Sciences Open access 16 Jul 2010 263
29 Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia Masamichi Mori, Naoki Kaneko, Yoko Ueno et al. · Investigational New Drugs Open access 17 May 2017 262
30 Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia Yukinori Nagakura, Tomoya Oe, Toshiaki Aoki et al. · Pain 31 Jul 2009 254
31 Fused-filament 3D printing of drug products: Microstructure analysis and drug release characteristics of PVA-based caplets Álvaro Goyanes, Masanori Kobayashi, Ramón Martı́nez-Pacheco et al. · International Journal of Pharmaceutics Open access Nov 2016 249
32 Antibacterial discovery in actinomycetes strains with mutations in RNA polymerase or ribosomal protein S12 Takeshi Hosaka, Mayumi Ohnishi‐Kameyama, Hideyuki Muramatsu et al. · Nature Biotechnology 26 Apr 2009 241
33 Computer-aided antibody design Daisuke Kuroda, Hiroki Shirai, Matthew P. Jacobson et al. · Protein Engineering Design and Selection Open access 2 Jun 2012 230
34 Identification of a selective ERK inhibitor and structural determination of the inhibitor–ERK2 complex Makoto Ohori, Takayoshi Kinoshita, Mitsuru Okubo et al. · Biochemical and Biophysical Research Communications 23 Aug 2005 229
35 NCCN Guidelines Insights: Bladder Cancer, Version 5.2018 Thomas W. Flaig et al. · Journal of the National Comprehensive Cancer Network Open access Sep 2018 220
36 Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis Haruhiko Ogata, Jun Kato, Fumihito Hirai et al. · Inflammatory Bowel Diseases Open access Sep 2011 211
37 Use of Amino Acid Composition to Predict Ligand-Binding Sites Shinji Soga, Hiroki Shirai, Masato Kobori et al. · Journal of Chemical Information and Modeling 23 Jan 2007 207
38 Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan Tadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi et al. · Journal of the American Society of Nephrology Open access 3 Jun 2020 205
39 Differential Effects between γ-Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice Yasuyuki Mitani, Junko Yarimizu, Kyoko Saita et al. · Journal of Neuroscience Open access 8 Feb 2012 198
40 SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats Masanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki et al. · European Journal of Pharmacology Open access 31 Jan 2014 198
41 Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo et al. · Bioorganic & Medicinal Chemistry 12 Jul 2006 196
42 Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade Shinsuke Nakao, Yukinori Arai, Mamoru Tasaki et al. · Science Translational Medicine 15 Jan 2020 191
43 Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway Motoharu Awazawa, Kohjiro Ueki, Kazunori Inabe et al. · Biochemical and Biophysical Research Communications Mar 2009 186
44 A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes Hiroyuki Ando, Takashi Yoshinaga, Wataru Yamamoto et al. · Journal of Pharmacological and Toxicological Methods Open access 10 Dec 2016 185
45 An Increase in Murine Skeletal Muscle Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α (PGC-1α) mRNA in Response to Exercise Is Mediated by β-Adrenergic Receptor Activation Shinji Miura, Kentaro Kawanaka, Yuko Kai et al. · Endocrinology Open access 20 Apr 2007 184
46 Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms Ryuta Wada, Makoto Matsui, Nana Kawasaki · mAbs Open access 24 Nov 2018 181
47 BIN1 favors the spreading of Tau via extracellular vesicles Andrea Crotti, Hameetha Rajamohamend Sait, Kathleen M. McAvoy et al. · Scientific Reports Open access Jul 2019 178
48 Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown Shuntaro Ogura et al. · JCI Insight Open access 8 Feb 2017 178
49 Formulation design of a novel fast-disintegrating tablet Takao Mizumoto, Yoshinori Masuda, Takeshi Yamamoto et al. · International Journal of Pharmaceutics 28 Oct 2005 178
50 Human and mouse adipose-derived cells support feeder-independent induction of pluripotent stem cells Shigeki Sugii, Yasuyuki S. Kida, Teruhisa Kawamura et al. · Proceedings of the National Academy of Sciences Open access 3 Feb 2010 178

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.